APOBEC3B and CD274 as Combined Biomarkers for Predicting Response to Immunotherapy in Urothelial Carcinoma of the Bladder

Figure 6

Validation of A3B in the IMvigor210 immunotherapy cohort. (a) Spearman correlation of A3B and CD274. (b) Survival analysis of the A3B combined with CD274 group. A3B and CD274 were divided into high and low expression groups based on the median value.

(a)

(b)